BiomX (PHGE) Expected to Announce Earnings on Tuesday
BiomX (NYSEAMERICAN:PHGE – Get Free Report) is anticipated to announce its earnings results before the market opens on ...
Nature11d
Secondary sclerosing cholangitis
The clinical picture of SSC resembles that of primary sclerosing cholangitis (PSC), with the presence of progressive hepatic fibrosis, multiple irregular biliary strictures and biliary dilatations.
Medical Xpress on MSN10d
Semisynthetic bile acid shows promise in reducing gut inflammation
NorUDCA (24-nor-ursodeoxycholic acid) is a chemically modified bile acid that has already shown promising results in the ...
Biotech Alert: Searches spiking for these stocks today
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: ...
ProQR Therapeutics price target raised to $12 from $10 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on ProQR Therapeutics (PRQR) to $12 from $10 and keeps a Buy rating on the shares. The firm says ...
Lawyer Monthly13d
Itching and Liver Disease: Causes, Effects, and Relief Options
Explore the causes of itching in liver diseases and tips to relieve discomfort. Learn about treatments for pruritus and when ...
News-Medical.Net on MSN8d
Semi-synthetic bile acid could be a promising therapeutic option for TH17-mediated intestinal diseases
A research team from the Medical University of Vienna has made further progress in the treatment of intestinal inflammation.
Science Daily8d
Focus on the gut-liver axis: Semisynthetic bile acid has anti-inflammatory effects on the gut
A research team has made further progress in the treatment of intestinal inflammation. A study shows that the semi-synthetic bile acid NorUDCA inhibits in the intestine the formation of ...